Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants and young children. The level of serum neutralizing antibodies (SNAs) is often used as a measure of protection against respiratory syncytial virus (RSV) infection.

Methods

A qualified, model-based, meta-analysis efficacy prediction framework was used to understand the maternal vaccination-induced fold-increase in SNA titers necessary to achieve, over several study observation periods and study populations, similar protection to that of the monoclonal antibody clesrovimab (MK-1654).

Results

Simulations indicated that 3-month and 6-month efficacy comparable to that predicted for passive immunization (clesrovimab) would require a maternal vaccine to increase SNA tite

SUBMITTER: Plock N 

PROVIDER: S-EPMC12003833 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature